Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 09, 2015 2:49 PM ET


Company Overview of RxGen, Inc.

Company Overview

RxGen, Inc. operates as a translational research company. It develops in vivo disease models to evaluate, select, and develop candidate therapeutics and drug delivery technologies. The company offers preclinical research models and services focusing on central nervous system, ophthalmic, and metabolic disorders. RxGen, Inc. is based in Hamden, Connecticut.

100 Deepwood Drive

Hamden, CT 06517

United States





Key Executives for RxGen, Inc.

Chief Executive Officer, Chief Scientific Officer, and Co-Founder
Vice-President, Chief Business Officer, and Co-Founder
Compensation as of Fiscal Year 2015.

RxGen, Inc. Key Developments

RxGen and ProLynx Present Data on Ocular Delivery Platform

RxGen and ProLynx LLC, presented primate study data showing that polyethylene glycols (PEGs) are appropriate supports to extend ocular pharmacokinetics of conjugated drugs at the Association for Research in Vision and Ophthalmology (ARVO) 2014 annual meeting in Orlando, FL. The study, performed in healthy adult African green monkeys, first evaluated the pharmacokinetics of intravitreally delivered fluorescein-labeled 20- to 80-kDa linear PEGs, and two, three and four arm 40 kDa PEGs. The fluorescein-PEG conjugates exhibited prolonged retention with half-lives of about five days that was not highly dependent on PEG size or shape, and had no apparent adverse effects. With the identification of PEGs as appropriate carrier molecules for ocular delivery ProLynx self-cleaving linkers were then used to attach fluorescent drug surrogates to demonstrate slow, controlled intravitreal release of the drug surrogate from the PEG support over time.

Similar Private Companies By Industry

Company Name Region
ImmuMed, Inc. United States
Hy BioPharma Inc. United States
Spyryx Biosciences, Inc. United States
Targazyme, Inc. United States
Apollo Biopharmaceutics United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RxGen, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at